An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Tolinapant (Primary)
- Indications Rectal cancer
- Focus Adverse reactions
- Acronyms PRAAR1
Most Recent Events
- 07 Feb 2024 Status changed from not yet recruiting to recruiting.
- 26 Jun 2023 New trial record